Logo-jpd
J parathyr dis. 2017;5(1): 17-24.
  Abstract View: 109
  PDF Download: 71

Original

Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients

Usman Kahlid Cheema 1, Armughan Ahmed 2, Chaudhary Muhammad Junaid Nazar 1 * , Ghias Uddin Butt 2, Aftab Cheema 3, Muhammad Bilal 3, Aisha Ashraf 3

1 Department of Nephrology and Renal Transplantation, Shifa International Hospital, Islamabad, Pakistan
2 Department of Nephrology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan
3 Department of Medicine, Shifa International Hospital, Islamabad, Pakistan
*Corresponding author: Chaudhary Muhammad Junaid Nazar, dr.cmjnazar@live.co.uk

Abstract

Introduction: Hyperphosphatemia is also known as a silent killer among patients with renal failure.

Objectives: The objectives of this investigation was to assess the efficiency and tolerability of sevelamer in hyperphosphatemia in Pakistani patients on regular hemodialysis.

Patients and Methods: A total of 59 dialysis individuals (age >18 years), from both genders, on regular hemodialysis with phosphate level more than 5.5 mg/dL, not on any phosphate binders was enrolled to the study. All the patients received sevelamer 400 mg orally in a dose depending on their baseline serum phosphorus level. Patients received the treatment for duration of 8 weeks. All the patients were followed and investigated for the efficacy and safety variables on fortnightly basis.

Results: The mean (± SD) age of all the enrolled patients was 42.2 (±6.4) years. The mean (±SD) serum phosphorus was reduced significantly to 6.70 (±0.86) mg/dL, 6.00 (±0.64) mg/dL, 5.30 (±0.87) mg/dL and 4.97 (±0.91) mg/dL on day 15 (P < 0.0001), 30 (P < 0.0001), 45 (P < 0.0001) and day 60 (P < 0.0001) respectively. The mean (SD) serum total cholesterol was also reduced non-significantly to 193.9 (±15.6) mg/dL, significantly to 192.1 (±15.9) mg/dL, to 190.6 (±17.0) mg/dL and to 188.1 (±16.3) mg/dL on day 15 (P = 0.085), day 30 (P = 0.003), day 45 (P < 0.0001), and on day 60 (P < 0.0001) respectively.

Conclusion: Our study showed a significant reduction in mean serum phosphorus and total cholesterol, in patients on hemodialysis. Therefore, sevelamer is a safe drug for the treatment of hyperphosphatemia in our clinical settings.

Keywords: End-stage renal disease, Chronic kidney disease, Hyperphosphatemia, Hemodialysis, Sevelamer
Please cite this paper as: Cheema UK, Ahmed A, Nazar CMJ, Butt GU, Cheema A, Bilal M, et al. Effectiveness and tolerability of sevelamer in the treatment of hyperphosphatemia in hemodialysis patients. J Parathyr Dis. 2017;5(1):17-24.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 109

Your browser does not support the canvas element.


PDF Download: 71

Your browser does not support the canvas element.

ePublished: 04 Sep 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)